Clinical phenotypes and prognostic features of embryonal tumours with multi-layered rosettes: a Rare Brain Tumor Registry study

Rare Brain Tumor Registry

Research output: Contribution to journalArticlepeer-review

9 Scopus citations


Background: Embryonal tumours with multi-layered rosettes (ETMRs) are a newly recognised, rare paediatric brain tumour with alterations of the C19MC microRNA locus. Due to varied diagnostic practices and scarce clinical data, disease features and determinants of outcomes for these tumours are poorly defined. We did an integrated clinicopathological and molecular analysis of primary ETMRs to define clinical phenotypes, and to identify prognostic factors of survival and key treatment modalities for this orphan disease. Methods: Paediatric patients with primary ETMRs and tissue available for analyses were identified from the Rare Brain Tumor Consortium global registry. The institutional histopathological diagnoses were centrally re-reviewed as per the current WHO CNS tumour guidelines, using histopathological and molecular assays. Only patients with complete clinical, treatment, and survival data on Nov 30, 2019, were included in clinicopathological analyses. Among patients who received primary multi-modal curative regimens, event-free survival and overall survival were determined using Cox proportional hazard and log-rank analyses. Univariate and multivariable Cox proportional hazard regression was used to estimate hazard ratios (HRs) with 95% CIs for clinical, molecular, or treatment-related prognostic factors. Findings: 159 patients had a confirmed molecular diagnosis of primary ETMRs (median age at diagnosis 26 months, IQR 18–36) and were included in our clinicopathological analysis. ETMRs were predominantly non-metastatic (94 [73%] of 128 patients), arising from multiple sites; 84 (55%) of 154 were cerebral tumours and 70 (45%) of 154 arose at sites characteristic of other brain tumours. Hallmark C19MC alterations were seen in 144 (91%) of 159 patients; 15 (9%) were ETMR not otherwise specified. In patients treated with curative intent, event-free survival was 57% (95% CI 47–68) at 6 months and 31% (21–42) at 2 years; overall survival was 29% (20–38) at 2 years and 27% (18–37) at 4 years. Overall survival was associated with non-metastatic disease (HR 0·48, 95% CI 0·28–0·80; p=0·0057) and non-brainstem location (0·42 [0·22–0·81]; p=0·013) on univariate analysis, as well as with gross total resection (0·30, 0·16–0·58; p=0·0014), high-dose chemotherapy (0·35, 0·19–0·67; p=0·0020), and radiotherapy (0·21, 0·10–0·41; p<0·0001) on multivariable analysis. 2-year event-free and overall survival was 0% at 2 years in patients treated with conventional chemotherapy without radiotherapy (regardless of surgery extent), and 21% (95% CI 1–41) and 30% (6–54), respectively, in patients treated with high-dose chemotherapy, and gross total resection without radiotherapy. 2-year event-free survival in patients treated with high-dose chemotherapy and radiotherapy was 66% (95% CI 39–93) for patients with gross total resection and 44% (7–81) for patients with sub-total resection. 2–5-year overall survival was 66% (95% CI 33–99, p=0·038) for patients with gross total resection and 67% (36–98, p=0·0020) for patients with sub-total resection. Interpretation: Prompt molecular diagnosis and post-surgical treatment with intensive multi-modal therapy tailored to patient-specific risk features could improve ETMR survival. Funding: Canadian Institute of Health Research, Canada Research Chair Awards, Australian Lions Childhood Cancer Research Foundation, Spanish Society of Pediatrics, Consejería de Salud y Familias de la Junta de Andalucía, Miracle Marnie, Phoebe Rose Rocks, Tali's Funds, Garron Cancer Centre, Grace's Walk, Meagan's Hug, Brainchild, Nelina's Hope, and Jean Martel Foundation.

Original languageEnglish (US)
Pages (from-to)800-813
Number of pages14
JournalThe Lancet Child and Adolescent Health
Issue number11
StatePublished - Nov 2021

Bibliographical note

Funding Information:
AH, NA, and EB conceived the project. TS, BH, PS-P, and SK analysed the methylation and clinical data with supervision from DS and AH; TS, SK, ML, and GRS performed histopathological and molecular analyses with assistance and supervision from MS, CH, and AH. Listed members of the Rare Brain Tumor Consortium provided patient-related materials or clinical data used in this study. SK and PS-P performed statistical analyses supported by VR and DS. AH provided overall supervision for the project and wrote the manuscript with SK and PS-P with input from all listed members of the Rare Brain Tumor Consortium. SK, PS-P, TS, EB, NA, and AH had access to all the data in the study and accept final responsibility to submit for publication.

Funding Information:
SK was supported by the Australian Lions Childhood Cancer Research Foundation and PS-P was supported by the Spanish Society of Pediatrics, Consejería de Salud y Familias de la Junta de Andalucía Project EF-0451-2017. This work was supported by funds from the Canadian Institute of Health Research ( grant number 137011 ). We are indebted to colleagues and patient families for supporting the Rare Brain Tumor Consortium's mission to translate knowledge to cure orphan brain tumours.

Publisher Copyright:
© 2021 Elsevier Ltd


Dive into the research topics of 'Clinical phenotypes and prognostic features of embryonal tumours with multi-layered rosettes: a Rare Brain Tumor Registry study'. Together they form a unique fingerprint.

Cite this